c-erbB-2 in serum of patients with breast cancer

被引：32

作者：

Harris, L ^{[1
]}

Luftner, D

Jäger, W

Robertson, JFR

机构：

[1] Duke Univ, Dept Hematol Oncol, Durham, NC 27706 USA

[2] Humboldt Univ, Schwerpunkt Onkol & Hamatol, Med Klin & Poliklin 2, D-1086 Berlin, Germany

[3] Univ Erlangen Nurnberg, Dept Gynecol & Obstet, D-8520 Erlangen, Germany

[4] City Hosp, Dept Surg, Nottingham NG5 1PB, England

来源：

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS | 1999年 / 14卷 / 01期

关键词：

breast cancer; c-erbB-2; serum;

D O I：

10.1177/172460089901400103

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

c-erbB-2 is an oncoprotein which is overexpressed in some breast cancers. Recently it has been established that the extracellular domain of c-erbB-2 is shed into the serum of patients with breast cancel: There appears to be no association between tumor stage and extracellular domain of c-erbB-2 (c-erbB-2/ECD): c-erbB-2/ECD seems to correlate with patient prognosis whatever the stage of disease. The data also suggest that c-erbB-2/ECD may be useful in monitoring for tumor recurrence and in predicting resistance to hormonal therapy, but not as useful in predicting response to chemotherapy. This may relate to the power of this marker to reflect disease burden, which has an overwhelmingly negative impact on outcome.

引用

收藏

页码：8 / 15

页数：8

相关论文

共 23 条

[1]

COLOMER R, 1997, P AN M AM SOC CLIN, V16, pA140

[2] HETERODIMERIZATION AND FUNCTIONAL INTERACTION BETWEEN EGF RECEPTOR FAMILY MEMBERS - A NEW SIGNALING PARADIGM WITH IMPLICATIONS FOR BREAST-CANCER RESEARCH [J].

EARP, HS ;

DAWSON, TL ;

LI, X ;

YU, H .

BREAST CANCER RESEARCH AND TREATMENT, 1995, 35 (01) :115-132

[3] Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients [J].

Fehm, T ;

Maimonis, P ;

Weitz, S ;

Teramoto, Y ;

Katalinic, A ;

Jager, W .

BREAST CANCER RESEARCH AND TREATMENT, 1997, 43 (01) :87-95

[4]

Harris LN, 1996, P AN M AM SOC CLIN, V15, P108

[5] Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers [J].

Hayes, DF ;

Bast, RC ;

Desch, CE ;

Fritsche, H ;

Kemeny, NE ;

Jessup, JM ;

Locker, GY ;

MacDonald, JS ;

Mennel, RG ;

Norton, L ;

Ravdin, P ;

Taube, S ;

Winn, RJ .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20) :1456-1466

[6] SOLUBLE C-ERBB-2 FRAGMENT IN SERUM CORRELATES WITH DISEASE STAGE AND PREDICTS FOR SHORTENED SURVIVAL IN PATIENTS WITH EARLY-STAGE AND ADVANCED BREAST-CANCER [J].

KANDL, H ;

SEYMOUR, L ;

BEZWODA, WR .

BRITISH JOURNAL OF CANCER, 1994, 70 (04) :739-742

[7] ELEVATED SERUM C-ERBB-2 ANTIGEN LEVELS AND DECREASED RESPONSE TO HORMONE-THERAPY OF BREAST-CANCER [J].

LEITZEL, K ;

TERAMOTO, Y ;

KONRAD, K ;

CHINCHILLI, VM ;

VOLAS, G ;

GROSSBERG, H ;

HARVEY, H ;

DEMERS, L ;

LIPTON, A .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1129-1135

[8] Plasma c-erbB-2 levels in breast cancer patients:: Prognostic significance in predicting response to chemotherapy [J].

Mehta, RR ;

McDermott, JH ;

Hieken, TJ ;

Marler, KC ;

Patel, MK ;

Wild, LD ;

Das Gupta, TK .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2409-2416

[9] Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases [J].

Molina, R ;

Jo, J ;

Filella, X ;

Bruix, J ;

Castells, A ;

Hague, M ;

Ballesta, AM .

TUMOR BIOLOGY, 1997, 18 (03) :188-196

[10] Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: Comparison with carcinoembryonic antigen and CA 15.3 [J].

Molina, R ;

Jo, J ;

Zanon, G ;

Filella, X ;

Farrus, B ;

Munoz, M ;

Latre, ML ;

Pahisa, J ;

Velasco, M ;

Fernandez, P ;

Estape, J ;

Ballesta, AM .

BRITISH JOURNAL OF CANCER, 1996, 74 (07) :1126-1131